
Sun Pharmaceutical Industries Ltd announced that the US health regulator has accepted their new drug application for deuruxolitinib, an investigational oral drug designed to treat adults with moderate to severe alopecia areata. Sun Pharma has submitted the 8 mg twice daily regimen of deuruxolitinib for review by the US Food and Drug Administration (USFDA). The company believes that deuruxolitinib holds the potential as a crucial treatment option for individuals dealing with the chronic nature of alopecia areata. The application is based on two pivotal Phase III trials involving over 1,200 patients across 135 clinical trial sites, with data presented at recent dermatology meetings.
Like
Save
Share